Article

3,000 contacts prescribed

SynergEyes Inc.?s second-generation silicone hydrogel hybrid contact lens (Duette) has been prescribed to more than 3,000 patients in 700 practices across 47 states since it became available nationwide Jan. 1, according to the company.

Carlsbad, CA-SynergEyes Inc.’s second-generation silicone hydrogel hybrid contact lens (Duette) has been prescribed to more than 3,000 patients in 700 practices across 47 states since it became available nationwide Jan. 1, according to the company.

“[The lens] represents the movement of hybrid contact lens technology from treating irregular corneas to providing an unprecedented combination of visual acuity and comfort to [patients with] normal cornea[s who] walk into the office every day,” said Kellie Kaseburg, vice president of global marketing for SynergEyes.

The hybrid lens technology, an alternative to soft toric contact lenses, incorporates materials for both the RGP center and the soft lens skirt. The high modulus RGP (MaxVu) has a Dk of 130 and class II UV blocker incorporated, whereas the high-Dk, low-modulus silicone hydrogel skirt has a Dk of 84 and is 32% water. A patent-pending surface treatment (HealthyEyes) is designed to increase wettability and resist protein deposits to maximize comfort.

The lens is designed to be rotationally symmetric, and to provide corneal astigmatism correction without inconsistent axis shift by using an optimized lacrimal layer to decrease aberrations and enhance optical performance, eliminating soft toric lens rotation issues such as blur, inconsistent vision, and less-than-optimal night vision, according to the company.

The hybrid contact lens is available in sphere powers of +4.00 to
–12.00 D and is offered in five base curves and three skirt curves. It is approved to correct up to 6.00 D of corneal astigmatism. Eye-care professionals interested in prescribing the lens should visit www.fitsynergeyes.com to inquire about a diagnostic fitting set.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.